AFP and hepatocellular carcinoma: AFP, as the most widely applied serum biomarker applied in HCC patient management, does not meet the clinical requirements, as demonstrated by its low sensitivity (only approximately 30%) in predicting tumor relapse and its weak associations with patient survival.42, 43